Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Dow
McKesson
Medtronic
Baxter
Boehringer Ingelheim
AstraZeneca

Last Updated: May 20, 2022

NURTEC ODT Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

Which patents cover Nurtec Odt, and what generic alternatives are available?

Nurtec Odt is a drug marketed by Biohaven Ireland and is included in one NDA. There are three patents protecting this drug.

This drug has ninety-six patent family members in thirty-four countries.

The generic ingredient in NURTEC ODT is rimegepant sulfate. Additional details are available on the rimegepant sulfate profile page.

DrugPatentWatch® Generic Entry Outlook for Nurtec Odt

Nurtec Odt will be eligible for patent challenges on February 27, 2024. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be February 25, 2033. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Sign up for a Free Trial

Summary for NURTEC ODT
International Patents:96
US Patents:3
Applicants:1
NDAs:1
Raw Ingredient (Bulk) Api Vendors: 31
Clinical Trials: 2
Patent Applications: 37
Drug Prices: Drug price information for NURTEC ODT
What excipients (inactive ingredients) are in NURTEC ODT?NURTEC ODT excipients list
DailyMed Link:NURTEC ODT at DailyMed
Drug patent expirations by year for NURTEC ODT
Drug Prices for NURTEC ODT

See drug prices for NURTEC ODT

DrugPatentWatch® Estimated Generic Entry Opportunity Date for NURTEC ODT
Generic Entry Date for NURTEC ODT*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET, ORALLY DISINTEGRATING;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for NURTEC ODT

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Antonios LikourezosPhase 4
Weill Medical College of Cornell UniversityPhase 2
Biohaven Pharmaceuticals, Inc.Phase 2

See all NURTEC ODT clinical trials

US Patents and Regulatory Information for NURTEC ODT

NURTEC ODT is protected by five US patents and two FDA Regulatory Exclusivities.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of NURTEC ODT is See Plans and Pricing.

This potential generic entry date is based on patent See Plans and Pricing.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting NURTEC ODT

Rimegepant for CGRP related disorders
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN ADULTS

Rimegepant for CGRP related disorders
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: PREVENTIVE TREATMENT OF EPISODIC MIGRAINE IN ADULTS

CGRP receptor antagonists
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN ADULTS

CGRP receptor antagonists
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: PREVENTIVE TREATMENT OF EPISODIC MIGRAINE IN ADULTS

N-(5S,6S,9R)-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-ctclohepta- [b]Pyridin-9-yl-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-carboxylat- e salt
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

FDA Regulatory Exclusivity protecting NURTEC ODT

NEW CHEMICAL ENTITY
Exclusivity Expiration: See Plans and Pricing

FOR THE PREVENTIVE TREATMENT OF EPISODIC MIGRAINE IN ADULTS
Exclusivity Expiration: See Plans and Pricing

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Biohaven Ireland NURTEC ODT rimegepant sulfate TABLET, ORALLY DISINTEGRATING;ORAL 212728-001 Feb 27, 2020 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Biohaven Ireland NURTEC ODT rimegepant sulfate TABLET, ORALLY DISINTEGRATING;ORAL 212728-001 Feb 27, 2020 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Biohaven Ireland NURTEC ODT rimegepant sulfate TABLET, ORALLY DISINTEGRATING;ORAL 212728-001 Feb 27, 2020 RX Yes Yes See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for NURTEC ODT

When does loss-of-exclusivity occur for NURTEC ODT?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Patent: 13226361
Estimated Expiration: See Plans and Pricing

Canada

Patent: 65585
Estimated Expiration: See Plans and Pricing

China

Patent: 4136437
Estimated Expiration: See Plans and Pricing

Croatia

Patent: 0171620
Estimated Expiration: See Plans and Pricing

Patent: 0191655
Estimated Expiration: See Plans and Pricing

Cyprus

Patent: 19448
Estimated Expiration: See Plans and Pricing

Denmark

Patent: 20016
Estimated Expiration: See Plans and Pricing

Patent: 54681
Estimated Expiration: See Plans and Pricing

Eurasian Patent Organization

Patent: 5358
Estimated Expiration: See Plans and Pricing

Patent: 1491585
Estimated Expiration: See Plans and Pricing

European Patent Office

Patent: 20016
Estimated Expiration: See Plans and Pricing

Patent: 54681
Estimated Expiration: See Plans and Pricing

Hong Kong

Patent: 48111
Estimated Expiration: See Plans and Pricing

Hungary

Patent: 34936
Estimated Expiration: See Plans and Pricing

Patent: 47050
Estimated Expiration: See Plans and Pricing

Israel

Patent: 4272
Estimated Expiration: See Plans and Pricing

Japan

Patent: 08154
Estimated Expiration: See Plans and Pricing

Patent: 76253
Estimated Expiration: See Plans and Pricing

Patent: 15511581
Estimated Expiration: See Plans and Pricing

Patent: 17226693
Estimated Expiration: See Plans and Pricing

Lithuania

Patent: 20016
Estimated Expiration: See Plans and Pricing

Patent: 54681
Estimated Expiration: See Plans and Pricing

Mexico

Patent: 2171
Estimated Expiration: See Plans and Pricing

Patent: 14009544
Estimated Expiration: See Plans and Pricing

Norway

Patent: 35439
Estimated Expiration: See Plans and Pricing

Poland

Patent: 20016
Estimated Expiration: See Plans and Pricing

Patent: 54681
Estimated Expiration: See Plans and Pricing

Portugal

Patent: 20016
Estimated Expiration: See Plans and Pricing

Patent: 54681
Estimated Expiration: See Plans and Pricing

Serbia

Patent: 556
Estimated Expiration: See Plans and Pricing

Patent: 295
Estimated Expiration: See Plans and Pricing

Singapore

Patent: 201404834X
Estimated Expiration: See Plans and Pricing

Slovenia

Patent: 20016
Estimated Expiration: See Plans and Pricing

Patent: 54681
Estimated Expiration: See Plans and Pricing

South Korea

Patent: 2076118
Estimated Expiration: See Plans and Pricing

Patent: 2220969
Estimated Expiration: See Plans and Pricing

Patent: 140130140
Estimated Expiration: See Plans and Pricing

Patent: 200016993
Estimated Expiration: See Plans and Pricing

Spain

Patent: 42737
Estimated Expiration: See Plans and Pricing

Patent: 46031
Estimated Expiration: See Plans and Pricing

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering NURTEC ODT around the world.

Country Patent Number Title Estimated Expiration
Spain 2441192 See Plans and Pricing
Slovenia 2820016 See Plans and Pricing
South Korea 101755742 See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Johnson and Johnson
Harvard Business School
McKesson
Baxter
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.